Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientif... ( SEATTLE Oct. 1 /- Trubion Pharmac...)

Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting

Date:10/1/2007

SEATTLE, Oct. 1 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that two abstracts, including its late-breaking abstract for TRU-015 for rheumatoid arthritis (RA), have been accepted for presentation at the American College of Rheumatology (ACR) Annual Scientific Meeting. This meeting will be held in conjunction with the Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting Nov. 6-11, 2007, at Boston's Convention and Exhibition Center.

Poster Presentations

Thursday, Nov. 8, 2007

Poster 309: Safety and Pharmacodynamics of Repeat Administration of TRU- 015, a CD20-Directed SMIP(TM) Therapeutic, in Subjects with Rheumatoid Arthritis

Friday, Nov. 9, 2007

Poster L7: TRU-015 Improves Rheumatoid Arthritis Disease Activity in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Dose Ranging Trial

Abstracts, including late-breaking, for the ACR Annual Scientific Meeting are now available online at http://www.rheumatology.org.

About Trubion

Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP custom drug assembly technology. In less than 24 months, the company designed, developed and submitted to the FDA an Investigational New Drug (IND) application for its lead product candidate, TRU-015, which has completed a Phase IIb clinical trial for the treatment of rheumatoid arthritis. In December 2005, the company entered into a collaboration agreement with Wyeth for th
'/>"/>

0

GOOD

Page: 1 2
Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition

Post Your Comments:

Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientif...( SEATTLE Oct. 1 /- Trubion Pharmac...)